Moreover, the 36-month beta value for BGNE is 0.58. Analysts have varying opinions on the stock, with 13 analysts rating it as a “buy,” 7 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for BGNE is 95.99M and currently, short sellers hold a 1.04% of that float. On December 02, 2024, BGNE’s average trading volume was 319.04K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BGNE) stock’s latest price update
The stock of BeiGene Ltd ADR (NASDAQ: BGNE) has decreased by -2.77 when compared to last closing price of 215.00. Despite this, the company has experienced a 9.73% gain in its stock price over the last five trading sessions. businesswire.com reported 2024-12-02 that SAN MATEO, Calif.–(BUSINESS WIRE)—- $BGNE #BeiGene–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will host an investor webcast on December 16, 2024 at 8:30 am EST. The Company’s R&D leadership team will provide an update on BeiGene’s innovative portfolio and pipeline, focusing on key presentations at the American Society of Hematology Meeting (ASH) and the San Antonio Breast Cancer Symposium. Th.
BGNE’s Market Performance
BeiGene Ltd ADR (BGNE) has experienced a 9.73% rise in stock performance for the past week, with a 3.16% rise in the past month, and a 11.04% rise in the past quarter. The volatility ratio for the week is 3.17%, and the volatility levels for the past 30 days are at 3.09% for BGNE. The simple moving average for the last 20 days is 5.20% for BGNE stock, with a simple moving average of 18.53% for the last 200 days.
Analysts’ Opinion of BGNE
Many brokerage firms have already submitted their reports for BGNE stocks, with JMP Securities repeating the rating for BGNE by listing it as a “Mkt Outperform.” The predicted price for BGNE in the upcoming period, according to JMP Securities is $288 based on the research report published on September 18, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see BGNE reach a price target of $185. The rating they have provided for BGNE stocks is “Overweight” according to the report published on February 06th, 2024.
Macquarie gave a rating of “Outperform” to BGNE, setting the target price at $259 in the report published on September 12th of the previous year.
BGNE Trading at -1.61% from the 50-Day Moving Average
After a stumble in the market that brought BGNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.76% of loss for the given period.
Volatility was left at 3.09%, however, over the last 30 days, the volatility rate increased by 3.17%, as shares surge +2.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.76% upper at present.
During the last 5 trading sessions, BGNE rose by +10.02%, which changed the moving average for the period of 200-days by +43.49% in comparison to the 20-day moving average, which settled at $198.74. In addition, BeiGene Ltd ADR saw 15.91% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BGNE starting from Wang Xiaodong, who sale 40,468 shares at the price of $190.10 back on Nov 26 ’24. After this action, Wang Xiaodong now owns 0 shares of BeiGene Ltd ADR, valued at $7,693,071 using the latest closing price.
Wang Xiaodong, the Chair, Scientific Advisory Brd of BeiGene Ltd ADR, sale 7,883 shares at $189.97 during a trade that took place back on Nov 26 ’24, which means that Wang Xiaodong is holding 0 shares at $1,497,499 based on the most recent closing price.
Stock Fundamentals for BGNE
Current profitability levels for the company are sitting at:
- -0.26 for the present operating margin
- 0.83 for the gross margin
The net margin for BeiGene Ltd ADR stands at -0.26. The total capital return value is set at -0.23. Equity return is now at value -23.90, with -15.15 for asset returns.
Based on BeiGene Ltd ADR (BGNE), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.42. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -98.35.
Currently, EBITDA for the company is -1.12 billion with net debt to EBITDA at 2.19. When we switch over and look at the enterprise to sales, we see a ratio of 6.47. The receivables turnover for the company is 5.5for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.93.
Conclusion
To wrap up, the performance of BeiGene Ltd ADR (BGNE) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
